Search results

2663 results

Sorted by Date . Sort by Relevance

  1. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

  2. The NICE strategy 2021 to 2026

    Dynamic, Collaborative, Excellent. The strategy sets out an ambitious vision for our future, building on the solid foundations of the last 22 years.

  3. Get involved

    We want you to tell us what matters to you, your organisation or your community.

  4. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  5. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults

  6. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults

  7. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence

  8. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  9. NICE support for local government

    The way public health services are planned and delivered in England has undergone major changes. Councils have been given a leading role to reduce...

  10. Indicator advisory committee (IAC)

    We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...

  11. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England.

  12. NICE International

    An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing

  13. For people with severe and symptomatic tricuspid regurgitation, evidence on the efficacy of transcatheter tricuspid valve leaflet repair is limited in quantity and quality. Evidence on its safety shows there are serious but well-recognised complications. Therefore, for these people, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG731/01 Question For people with severe and symptomatic tricuspid regurgitation, evidence on the efficacy of transcatheter

  14. For people with mild or moderate tricuspid regurgitation, evidence on the safety and efficacy of transcatheter tricuspid valve leaflet repair is inadequate in quantity and quality. Therefore, for these people, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    Recommendation ID IPG731/02 Question For people with mild or moderate tricuspid regurgitation, evidence on the safety and efficacy of transcatheter

  15. The effect of drug therapy for concurrent conditions on melanoma survival: In people diagnosed with melanoma what is the effect of drug therapy to treat concurrent conditions on disease specific survival? This should be investigated in a national prospective cohort study. Secondary outcomes should include overall survival and quality of life.

    Recommendation ID NG14/10 Question The effect of drug therapy for concurrent conditions on melanoma survival: In people diagnosed with

  16. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    Recommendation ID NG14/07 Question Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions:

  17. Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This should be investigated in a placebo controlled randomised trial. Secondary outcomes should include disease specific survival and toxicity, including the development of renal stones and hypercalcaemia.

    Recommendation ID NG14/09 Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve

  18. Surgical excision for people with lentigo maligna: For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face) how effective is Mohs micrographic surgery, compared with excision with a 0.5 cm clinical margin, in preventing biopsy proven local recurrence at 5 years? This should be investigated in a randomised controlled trial. Secondary outcomes should include cosmetic and functional outcomes.

    Recommendation ID NG14/08 Question Surgical excision for people with lentigo maligna: For people with lentigo maligna (stage 0 in sun damaged

  19. A high-quality test accuracy study is needed for the BRAHMS sFlt‑1 Kryptor/BRAHMS PLGF plus Kryptor PE ratio test, using thresholds defined by the company, done in a population independent from that used to establish the test's thresholds, and with the test used as intended in the NHS. Further research is recommended on repeat PLGF (placental growth factor)‑based testing, with standard clinical assessment, in women presenting with suspected preterm pre-eclampsia, who have had a previous PLGF‑based test result (see section 3.7 ). This should include: - exploring the different scenarios in which repeat testing may be indicated - the appropriate intervals between PLGF‑based tests - the diagnostic accuracy of repeat PLGF‑based testing in women with suspected preterm pre-eclampsia. Further research is recommended into how well the tests work when women are pregnant with more than 1 baby to find out if different cut-offs are needed (see section 3.15 ).

    Recommendation ID DG49/01 Question A high-quality test accuracy study is needed for the BRAHMS sFlt‑1 Kryptor/BRAHMS PLGF plus Kryptor

  20. For people with mild or moderate tricuspid regurgitation, evidence on the safety and efficacy of transcatheter tricuspid valve annuloplasty is inadequate in quantity and quality. Therefore, for these people, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    Recommendation ID IPG730/02 Question For people with mild or moderate tricuspid regurgitation, evidence on the safety and efficacy of transcatheter

  21. For people with severe and symptomatic tricuspid regurgitation, evidence on the efficacy of transcatheter tricuspid valve annuloplasty is limited in quantity and quality. Evidence on its safety shows there are serious but well-recognised complications. Therefore, for these people, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG730/01 Question For people with severe and symptomatic tricuspid regurgitation, evidence on the efficacy of transcatheter

  22. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

  23. Targeted support: What is the effectiveness (including long-term effectiveness) and cost effectiveness of targeted group or individual interventions for children and young people who have been identified as needing additional mental health support, and does it vary by ethnicity, socioeconomic status or other cultural and personal factors?

    Recommendation ID NG223/03 Question Targeted support: What is the effectiveness (including long-term effectiveness) and cost effectiveness

  24. Early signs of poor social, emotional and mental wellbeing: What are the early signs of social, emotional and mental wellbeing issues, including in children and young people who are internalising it? a) What early factors predict poor social, emotional and mental wellbeing? b) How do children and young people with poor social, emotional and mental wellbeing describe their thoughts and feelings at early onset stage? c) What are the barriers and facilitators to identifying children and young people at risk of poor social, emotional and mental wellbeing at school?

    Recommendation ID NG223/01 Question Early signs of poor social, emotional and mental wellbeing: What are the early signs of social, emotional